期刊
BRITISH JOURNAL OF CANCER
卷 104, 期 4, 页码 545-553出版社
SPRINGERNATURE
DOI: 10.1038/sj.bjc.6606031
关键词
glioma; glioblastoma; gene expression profiling; microarrays; personalised therapy; prognosis
类别
资金
- US National Cancer Institute [CA143848]
- US Department of Defense [W81XWH-09-2-0042]
- Damon Runyon Cancer Research Foundation [CI-45-09]
- UNC
The development of DNA microarray technologies over the past decade has revolutionised translational cancer research. These technologies were originally hailed as more objective, comprehensive replacements for traditional histopathological cancer classification systems, based on microscopic morphology. Although DNA microarray-based gene expression profiling (GEP) remains unlikely in the near term to completely replace morphological classification of primary brain tumours, specifically the diffuse gliomas, GEP has confirmed that significant molecular heterogeneity exists within the various morphologically defined gliomas, particularly glioblastoma (GBM). Herein, we provide a 10-year progress report on human glioma GEP, with focus on development of clinical diagnostic tests to identify molecular subtypes, uniquely responsive to adjuvant therapies. Such progress may lead to a more precise classification system that accurately reflects the cellular, genetic, and molecular basis of gliomagenesis, a prerequisite for identifying subsets uniquely responsive to specific adjuvant therapies, and ultimately in achieving individualised clinical care of glioma patients. British Journal of Cancer (2011) 104, 545-553. doi:10.1038/sj.bjc.6606031 www.bjcancer.com Published online 30 November 2010 (C) 2011 Cancer Research UK
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据